USPTO serial 79374320
ALGENSCRIBE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 25, 2024
- Examiner
- FLEMING, STEPHANIE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ALGENSCRIBE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cathleen E. Stadecker
Cathleen E. Stadecker Downs Rachlin Martin PLLC199 Main Street, PO Box 190Burlington, VT 05401United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical, biotechnological products intended for use in industry, science, agriculture, horticulture, namely, chemical and biochemical preparations for scientific purposes, chemicals for use in biotechnological product development, chemicals and biochemicals used in industry; Chemical, biochemical, biotechnological and bacteriological products for use in research and testing laboratories, namely, chemical and biochemical preparations for research purposes, chemicals for use in biotechnological product development, other than for medical or veterinary purposes; Chemical and biochemical preparations used in the manufacture of pharmaceuticals; Biotechnological products used in the manufacture of pharmaceuticals, namely, chemicals for use in biotechnological product development; Chemical preparations used for the production of gene and cell therapies; Diagnostic preparations other than for medical use; Diagnostic reagents and preparations for scientific use; Diagnostic reagents and preparations for scientific laboratories; Reagents for analytical use, namely, chemical analysis reagents other than for medical or veterinary purposes; Reagents for the extraction, preservation and processing of human, animal, plant or microbiological samples for collecting genetic or genomic information other than for medical or veterinary purposes; Diagnostic testing preparations, namely, reagents and assays for scientific use | ACTIVE | — |
| 005 | Veterinary and pharmaceutical preparations, namely, gene-based and cell-based therapeutic preparations for treating cancer; Pharmaceutical preparations for gene and cell therapy; Biological preparations for use in gene therapy and cell therapy for medical purposes; Micro-organism cultures and preparations for medical, pharmaceutical and/or veterinary use; Bacteriological preparations for medical, pharmaceutical and/or veterinary use; Diagnostic reagents and preparations for clinical, medical, pharmaceutical and/or veterinary use; Diagnostic test preparations consisting principally of reagents and assays for clinical, medical, pharmaceutical and/or veterinary use | ACTIVE | — |
| 042 | Scientific and industrial research, namely, chemical research, research and development of new biological and medical products; Scientific genetic, medical, pharmaceutical and veterinary research; Scientific genetic, medical, pharmaceutical and veterinary research, namely, research in the field of pharmaceutical preparations for gene and cell therapy; Research in chemistry, biology, biochemistry, molecular biology; Scientific research in the field of biology, genetics and genomics; Scientific research services using genomic analysis procedures; Biological, scientific genetic and genomic handling and analysis services for scientific use; Structural and functional genome analysis, for scientific purposes; Biotechnological research and development for third parties, including scientific feasibility studies on genetic associations, genome mapping, genome analysis and genome scanning; Scientific analysis in the field of genetics and genomics; Scientific research and development of biochemical analysis, biological analysis and molecular biology techniques; Research and development of new molecules intended for use in industry, preparing and providing biological materials and particularly stem cells; Developing pharmaceutical drugs and therapeutics; Scientific laboratory services, namely, biological material modifications | ACTIVE | — |
| 044 | Medical diagnostic services, including diagnostic and reagent sample testing services for third parties; Genetic testing for medical purposes, including genome mapping, genome analysis and genome scanning; Biological, genetic and genomic handling and analysis services for medical use; Medical genetic or genomic testing for detecting risks, diagnosing illness or selecting treatment in humans, animals or plants | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ALGENSCRIBE
- Other trademarks owned by ALGENSCRIBE
- Other trademarks owned by ALGENSCRIBE
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ALGENSCRIBE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 1, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 21, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 13, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 13, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 24, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 24, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 24, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 23, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 25, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 25, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 16, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 27, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 27, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 20, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 13, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 29, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 12, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 11, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 21, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 17, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 13, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |